Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Autor: Yousef Al Saleh, Noor Al Busaidi, Waleed Al Dahi, Munawar Almajnoni, Al Saeed Mohammed, Khalid Alshali, Mostafa Al-Shamiri, Saud Al Sifri, Mohammed Arafah, Siew Pheng Chan, Hassan El-Tamimi, Khadija Hafidh, Mohamed Hassanein, Ashraf Shaaban, Ali Sultan, Guido Grassi
Přispěvatelé: Al Saleh, Y, Al Busaidi, N, Al Dahi, W, Almajnoni, M, Mohammed, A, Alshali, K, Al-Shamiri, M, Al Sifri, S, Arafah, M, Chan, S, El-Tamimi, H, Hafidh, K, Hassanein, M, Shaaban, A, Sultan, A, Grassi, G
Rok vydání: 2023
Předmět:
Zdroj: Advances in Therapy.
ISSN: 1865-8652
0741-238X
DOI: 10.1007/s12325-023-02529-7
Popis: Type 2 diabetes mellitus (T2DM) and hypertension are leading risk factors for death and disability in the Middle East. Both conditions are highly prevalent, underdiagnosed and poorly controlled, highlighting an urgent need for a roadmap to overcome the barriers to optimal glycaemic and blood pressure management in this region. This review provides a summary of the Evidence in Diabetes and Hypertension Summit (EVIDENT) held in September 2022, which discussed current treatment guidelines, unmet clinical needs and strategies to improve treatment outcomes for patients with T2DM and hypertension in the Middle East. Current clinical guidelines recommend strict glycaemic and blood pressure targets, presenting several treatment options to achieve and maintain these targets and prevent complications. However, treatment targets are infrequently met in the Middle East, largely due to high clinical inertia among physicians and low medication adherence among patients. To address these challenges, clinical guidelines now provide individualised therapy recommendations based on drug profiles, patient preferences and management priorities. Efforts to improve the early detection of prediabetes, T2DM screening and intensive, early glucose control will minimise long-term complications. Physicians can use the T2DM Oral Agents Fact Checking programme to help navigate the wide range of treatment options and guide clinical decision-making. Sulfonylurea agents have been used successfully to manage T2DM; a newer agent, gliclazide MR (modified release formulation), has the advantages of a lower incidence of hypoglycaemia with no risk of cardiovascular events, weight neutrality and proven renal benefits. For patients with hypertension, single-pill combinations have been developed to improve efficacy and reduce treatment burden. In conjunction with pragmatic treatment algorithms and personalised therapies, greater investments in disease prevention, public awareness, training of healthcare providers, patient education, government policies and research are needed to improve the quality of care of patients with T2DM and/or hypertension in the Middle East.
Databáze: OpenAIRE
Externí odkaz: